Qualigen Therapeutics, Inc. (QLGN)

NASDAQ: QLGN · IEX Real-Time Price · USD
1.80
+0.30 (20.20%)
At close: Dec 1, 2022 4:00 PM
1.77
-0.03 (-1.67%)
After-hours: Dec 1, 2022 7:11 PM EST
20.2%
Market Cap 6.31M
Revenue (ttm) 5.07M
Net Income (ttm) -18.33M
Shares Out 3.94M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Nov 23, 2022
Volume 349,933
Open 1.5
Previous Close 1.5
Day's Range 1.48 - 1.93
52-Week Range 1.42 - 16.7
Beta 0.06
Analysts Buy
Price Target 4.85 (+169.4%)
Earnings Date Nov 21, 2022

About QLGN

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based trea... [Read more]

Industry Biotechnology
Founded 1996
CEO Andrew Ritter
Employees 39
Stock Exchange NASDAQ
Ticker Symbol QLGN
Full Company Profile

Financial Performance

In 2021, QLGN's revenue was $5.65 million, an increase of 1.72% compared to the previous year's $5.56 million. Losses were -$17.90 million, 901.2% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for QLGN stock is "Buy." The 12-month stock price forecast is 4.85, which is an increase of 169.44% from the latest price.

Price Target
$4.85
(169.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Action to comply with continued listing requirements for Nasdaq Capital Market

1 week ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Q3 2022 FastPack ® sales increased approximately 25% year-over-year Company continues to execute on and advance core therapeutic programs

2 weeks ago - GlobeNewsWire

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Fou r th RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models

1 month ago - GlobeNewsWire

Qualigen Therapeutics to Present at LD Micro Main Event XV

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with ...

1 month ago - GlobeNewsWire

Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

Posters include data regarding 1) m ode of action , and 2) preclinical toxicology

2 months ago - GlobeNewsWire

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with ...

3 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Q2 2022 FastPack ® Sales increased approximately 28 %, and gross profit on product sales was up 64% year-over-year from Q2 2021

3 months ago - GlobeNewsWire

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with ...

4 months ago - GlobeNewsWire

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Stu...

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with ...

4 months ago - GlobeNewsWire

Qualigen Therapeutics to Present at BIO International Convention

CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with ...

5 months ago - GlobeNewsWire

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

A P otential T reatment for Pancreatic Cancer in A ddition to O ther T umors of H igh U nmet C linical N eed

5 months ago - GlobeNewsWire

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex

Transaction expected to significantly advance commercial readiness of Nano S ynex' s innovative diagnostic s technology platform focused on the $30+ Billion global infectious disease testing market

5 months ago - GlobeNewsWire

Qualigen Therapeutics' Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2...

Abstracts Highlight In Vitro and In Vivo Activity of Qualigen's Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors

6 months ago - GlobeNewsWire

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with p...

6 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with p...

6 months ago - GlobeNewsWire

Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel

Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold

6 months ago - GlobeNewsWire

Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex

Compan ies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “ Superbugs , ” a Rising Global Health Crisis

6 months ago - GlobeNewsWire

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with...

7 months ago - GlobeNewsWire

Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Other symbols: ATNMLIXTPTE
7 months ago - InvestorPlace

Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers

Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR). QN-302 showed potent anti-proliferative activity in a prosta...

7 months ago - Benzinga

Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference

Data Highlights In V ivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers

7 months ago - GlobeNewsWire

Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®

Company Prepared for Growth and Improved Profitability of its Diagnostics Business

7 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results

CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with...

8 months ago - GlobeNewsWire

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with...

8 months ago - GlobeNewsWire

Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference

Abstracts Review Positive In vivo Data an d the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers

8 months ago - GlobeNewsWire